THREE EAST COAST POT STOCKS SET TO CATCH FIRE

PENNY POT PROFITS

THREE EAST COAST POT STOCKS SET TO CATCH FIRE

HOW TO CASH IN ON "CHECKMATE" PROFITS FROM MARIJUANA LEGALIZATION

SEVEN FIGURE

PUBLISHING

Three East Coast Pot Stocks Set to Catch Fire

How to Cash In On "Checkmate" Profits From Marijuana Legalization

With the East Coast starting a brand new wave of legalization, there's never been a better time to invest in penny pot stocks for huge, lightning-fast gains. The kind of gains that could kick-start your retirement in just a month... At the rate at which the marijuana industry is taking off, you can't afford to waste any time. So let's get started with three opportunities to kick start your profits...

Opportunity #1: A Canadian Pot Stock Ready To Rocket

Canadian pot stocks have been gaining traction thanks to insulation from the flux surrounding the U.S. pot market right now. That's giving us an opportunity to pull the trigger on this Canadian pot play. I'm talking about shares of Emerald Health Therapeutics Inc. (OTCBB: EMHTF). I had the pleasure of sitting down with Emerald's executive chairman, Avtar Dhillon, MD, in Las Vegas while visiting MJBizCon back in November. Dhillon's business background is actually biotech, and I've had occasion to speak to him over the years about several companies he's been involved with. As director of the Cannabis Canada Association, Dhillon is also fully plugged in and connected to the emerging cannabis industry up north. Recently, Emerald bought out its first 150,000-square-foot growing facility. It's on track to produce almost 50,000 kg by 2020. The company retains an option to develop an additional 3.7 million square feet and meet a substantial portion of Canadian demand. It's an exciting story -- and you'll hear a lot more about it as the story unfolds. In the meantime, here's how to trade it Action to take: Buy shares of Emerald Health Therapeutics Inc. (OTCBB: EMHTF) up to $5.50

Opportunity #2: A New Opportunity Emerges From Big Pharma

There's an immense opportunity in the pharmaceutical cannabis space right now. Recall marijuana has some incredible anti-inflammatory properties. And some of the world's most innovative drug makers are working hard to take those characteristics and turn them into targeted medicine for immune system diseases like cystic fibrosis, rheumatoid arthritis and scores more. Cannabis-focused pharma firms have some big advantages in this market. For starters, their work has mostly gone under the radar. The backward federal classification of marijuana has made it incredibly hard to secure permission to do research on the plant itself. So scientists are only just beginning to get a grasp on the mechanisms behind pot's potency as medicine.

2

We're at the start of a pharma revolution for pot! Plus, because of the added protections for legal medical uses of pot, cannabis-focused pharma stocks don't carry the same risks of federal policy changes that shook the legal marijuana market last month. For all of those reasons, it's time to pull the trigger on a new pot play! I'm recommending shares of small-cap pharma stock Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP). Corbus is developing a drug called lenabasum, a synthetic oral endocannabinoid-mimetic drug that's designed to treat rare, serious and chronic inflammatory diseases. At the same time, the past market correction is giving us an opportunity to get into shares near the bottom of the uptrend that's been intact since the start of last summer. Here's how to trade it: Action to take: Buy shares of Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP) up to $8.

Opportunity #3: Pot Hits a Major Exchange

We recently witnessed a huge update in the cannabis market -- pot hit a major U.S. exchange. Cronos Group Inc. (NASDAQ: CRON) officially opened for trading on the Nasdaq market back in late February, becoming the first pot producer and seller to be listed on a U.S. exchange. The U.S.-traded pot stocks already in our portfolio are either OTC stocks, or aren't directly in the business of growing and selling marijuana (like pharma companies, for instance). That's an important distinction -- since most investors focus only on listed stocks, Cronos has a wider potential market of investors than other pot stocks. It's an important validation for the marijuana market as a whole -- a pot grower is now officially part of the Nasdaq! But the other opportunity here is in shares of Cronos itself. I've been closely watching this stock since it went public. At the time, the price action didn't look ideal. The broad pot market was still in the middle of its correction. But now, with shares of CRON about 16% lower, I think we have a buying opportunity. Don't let Cronos' U.S. stock listing fool you -- it's a Canadian pot stock. That's likely why the company was able to get the green light from regulators at the SEC and Nasdaq. The firm owns a handful of cannabis businesses that operate in Canada, as well as interests in other markets where pot is legal at a national level. That puts it right in line with the other trades in our portfolio. Simply put, it's the pot story that's working in this market. And now, with the price action showing upside potential, it makes sense to buy. Shares are dipping this afternoon, giving us a chance to get in near the lows. Here's how to trade it... Action to Take: Buy shares of Cronos Group Inc. (NASDAQ: CRON) up to $8.55

A Final Note

Remember, these are still a small, speculative pot stocks. Use a limit order to place your buy, and don't chase shares. Likewise, don't risk money you can't afford to lose on your pot investments -- the same forces that make

3

these stocks potentially explosive gainers also make them riskier than the blue chips you probably hold in your retirement account. Follow our suggested prices and allocations as closely as possible to keep those risks in check. Don't worry -- I will keep a close eye on all of these positions for you -- and update you as things develop. When it is time to exit any of the trades above -- I'll send you an email. To a bright future, Ray Blanco

Copyright by Seven Figure Publishing a division of Agora Financial, LLC. 1117 St. Paul Street, Baltimore, MD 21201. All rights reserved. No part of this report may be reproduced by any means or for any reason without the consent of the publisher. The information contained herein is obtained from sources believed to be reliable; however, its accuracy cannot be guaranteed.

4

 ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download